Ginkgo seed extracts show antibacterial activity on skin pathogens
(Emory Health Sciences) Extracts from the seeds of the Ginkgo biloba tree show antibacterial activity on pathogens that can cause skin infections such as acne, psoriasis, dermatitis and eczema. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 18, 2019 Category: Infectious Diseases Source Type: news

DLQI With ‘ Not Relevant ’ Answers May Underrate Psoriasis Severity
Objective, subjective disease severity worse for those responding'not relevant'versus'not at all'(Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - April 11, 2019 Category: Psychiatry Tags: Dermatology, Psychiatry, Journal, Source Type: news

DLQI With'Not Relevant' Answers May Underrate Psoriasis Severity
THURSDAY, April 11, 2019 -- The Dermatology Life Quality Index (DLQI) may underestimate disease severity in patients with psoriasis who respond " not relevant " to one or more items, according to a research letter published online April 10 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 11, 2019 Category: Pharmaceuticals Source Type: news

Bristol part of € 20.8M study to drive drug discovery for atopic dermatitis and psoriasis
The lives of patients affected by atopic dermatitis and psoriasis could be improved thanks to the start of an EU-funded research project BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis). The five-year project will address key unmet needs in treating these common inflammatory skin conditions by analysing data from more than 50 000 patients to improve disease understanding, patient care and future therapies. (Source: University of Bristol news)
Source: University of Bristol news - April 11, 2019 Category: Universities & Medical Training Tags: Grants and Awards, Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Population Health Sciences, Institutes, ALSPAC; Press Release Source Type: news

Bristol part of € 20.8 million study to drive drug discovery for atopic dermatitis and psoriasis
The lives of patients affected by atopic dermatitis and psoriasis could be improved thanks to the start of an EU-funded research project BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis). The five-year project will address key unmet needs in treating these common inflammatory skin conditions by analysing data from more than 50 000 patients to improve disease understanding, patient care and future therapies. (Source: University of Bristol news)
Source: University of Bristol news - April 11, 2019 Category: Universities & Medical Training Tags: Grants and Awards, Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Population Health Sciences, Institutes, ALSPAC; Press Release Source Type: news

Why Does Medicine Cost So Much? Here ’s How Drug Prices Are Set
From 2007 to 2016, Mylan raised the list price of its EpiPen about 500%, from just under $100 to more than $600. From 2002 to 2013, insulin prices more than tripled. From 2012 to 2019, the average price of AbbVie’s rheumatoid-arthritis drug Humira climbed from $19,000 a year to $60,000 a year—and that’s after rebates. These are dramatic examples of a systemwide problem: prices for brand-name drugs are rising at a rate that far outstrips inflation. What’s behind these rapid price hikes? It’s a simple question with a complicated answer that involves three central entities: drug manufacturers, ph...
Source: TIME: Health - April 9, 2019 Category: Consumer Health News Authors: Laura Entis Tags: Uncategorized medicine Source Type: news

Man, 28, cannot walk, wear clothes or have sex due to his agonising psoriasis
Jassem Ahmed, of London, discovered flaky patches of skin behind his ears when he was 19, which spread to his entire body. Now 28, he has not left the house in two months. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2019 Category: Consumer Health News Source Type: news

Woman who spent YEARS using makeup to cover psoriasis
Sophia Chen, 20, from Colorado developed guttate psoriasis at the age 16. She went to see five dermatologists who advised her to try chemotherapy and sunbeds to cure condition. (Source: the Mail online | Health)
Source: the Mail online | Health - April 2, 2019 Category: Consumer Health News Source Type: news

Drug Survival Rates Highest for Ustekinumab for Pediatric Psoriasis
THURSDAY, March 28, 2019 -- In real-life conditions, drug survival rates are higher for ustekinumab than for adalimumab and etanercept for all treatments and types of psoriasis in children, according to a study published online March 18 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
This marks the first regulatory approval globally for SKYRIZI™ (risankizumab) SKYRIZI is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit[1] NORTH CHICAGO, Ill., March 26, 20... Biopharmaceuticals, Regulatory AbbVie, SKYRIZI, risankizumab, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 26, 2019 Category: Pharmaceuticals Source Type: news

Infliximab and Risk of Serious Infection in Psoriasis Infliximab and Risk of Serious Infection in Psoriasis
Does infliximab increase the risk of serious infection as compared to nonbiologic systemic therapies in patients with psoriasis?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Three psoriasis sufferers share their incredible transformations after using a three-step regime 
EXCLUSIVE: Jude Osborne, 45, Lucy Jones, 40, and Dave Brooks, 54, from the UK, saw 95 per cent of their flaky, dry skin calmed by Soratinex products. (Source: the Mail online | Health)
Source: the Mail online | Health - March 22, 2019 Category: Consumer Health News Source Type: news

Trendy 'celery juice' diet endorsed by Kim Kardashian could be giving you WRINKLES
Kim Kardashian drinks celery juice to help her psoriasis. But Emma Wedgeworth, a dermatologist from London, said it increases the skin's sensitivity to UVA in sunlight. (Source: the Mail online | Health)
Source: the Mail online | Health - March 21, 2019 Category: Consumer Health News Source Type: news

Brodalumab as an Alternative to Ustekinumab in Psoriasis Brodalumab as an Alternative to Ustekinumab in Psoriasis
Is brodalumab effective in treating moderate-to-severe psoriasis in patients who do not achieve adequate response with ustekinumab?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 18, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors 400 participants to be enrolled in Phase III study at 30 sites ... Biopharmaceuticals, Generics, Dermatology Alvotech, HUMIRA, biosimilar, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 13, 2019 Category: Pharmaceuticals Source Type: news

Book Review: Living Light:  The Art of Using Light for Health & Happiness
While it’s hard not to notice the brilliant display of colors set off by a sunset over the water, we seldom consider the biological, or even psychological, benefits of light. “It is my belief that good quality light in our daily lives is far more important than we might think,” writes Karl Ryberg. In his new book, Living Light: The Art of Using Light For Health And Happiness, Ryberg brings us his life’s work — studying the obvious and not so obvious ways in which light affects us and how we can use light in our lives not only function better, but feel better. Light, we know, plays an important...
Source: Psych Central - March 10, 2019 Category: Psychiatry Authors: Claire Nana Tags: Book Reviews Disorders General Habits Psychology Seasonal Affective Disorder Self-Help Treatment artificial light Light therapy Living Light natural light Ryberg SAD Source Type: news

‘Patient-Controlled’ Injector Approved for Tremfya
Patients now have another option for injecting Tremfya—a drug-delivery device designed specifically for patients. FDA has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. TREMFYA is given as a 100-mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4, Janssen Pharmaceutical Companies of Johnson & Johnson reported. Tremfya One-Press may be used by patients for self-injection with doctor approval and proper training, it was reported. West Pharmaceutical Services Inc. supplied the device. O...
Source: MDDI - March 9, 2019 Category: Medical Devices Authors: Daphne Allen Tags: Design Source Type: news

Durable Urticaria Control With Anti-IgE Drug
(MedPage Today) -- BTK inhibitor for pemphigus, anti-IL-36 drug for pustular psoriasis show early promise at AAD (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 7, 2019 Category: Primary Care Source Type: news

When Not to Use Biologics for Psoriasis
(MedPage Today) -- Comorbidities, special populations, idiosyncrasies influence decisions (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 6, 2019 Category: American Health Source Type: news

NEJM-IL-36-Phase-1-GPP-data
Novel antibody shows potential to transform treatment of rare form of psoriasisPublished in The New England Journal of Medicine, new data show single dose BI 655130* rapidly cleared symptoms of a rare and potentially life-threatening form of pustular psoriasis1BI 655130 is an investigational, potential first-in-class treatment targeting interleukin-36 receptor (IL-36R)BI 655130 is being studied in generalised pustular psoriasis as the first of several potential indications, including inflammatory bowel diseases  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 6, 2019 Category: Research Source Type: news

UCLA-led study could point to ways to better control inflammation in autoimmune diseases
In autoimmune diseases such as psoriasis or lupus, the immune system goes into overdrive in response to people ’s own DNA being released from damaged cells — a reaction that can cause severe inflammation in the body.Until now, the molecular processes behind that immune response have not been fully understood by scientists, but a new UCLA-led study could help change that.Researchers at UCLA and three other institutions discovered that LL37 molecules, which are found in the immune system, play an important but unexpected role in revving up the body ’s self-defense response. The finding may bring scientists ...
Source: UCLA Newsroom: Health Sciences - March 5, 2019 Category: Universities & Medical Training Source Type: news

Durable Psoriasis Responses With Dual IL-17 Inhibition
(MedPage Today) -- PASI90/100 responses maintained to 60 weeks with bimekizumab (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 5, 2019 Category: Dermatology Source Type: news

Glucose Metabolism in Patients With Psoriasis Glucose Metabolism in Patients With Psoriasis
This study aimed to elucidate the pathophysiological link between psoriasis, glucose metabolism, and T2DM.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Novartis data confirm rapid response and high efficacy of Cosentyx ® in psoriasis patients for first time in China
Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16. (Source: World Pharma News)
Source: World Pharma News - March 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Navigating the Biological Maze in Psoriasis
(MedPage Today) -- Higher response rates with newer drugs but older ones still provide good results (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 3, 2019 Category: Dermatology Source Type: news

Novel Agent Reduces Severe Pruritus in Psoriasis Novel Agent Reduces Severe Pruritus in Psoriasis
Serlopitant, an oral neurokinin-1 receptor antagonist, blocks the sensation of itch in the brain and reduces pruritus associated with psoriasis, new phase 2 research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2019 Category: Consumer Health News Tags: Dermatology News Source Type: news

EU Panel Backs Risankizumab (Skyrizi) for Plaque Psoriasis EU Panel Backs Risankizumab (Skyrizi) for Plaque Psoriasis
The interleukin-23 inhibitor is for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news

Age, Race Impact Atherosclerotic Risk With Psoriasis
FRIDAY, March 1, 2019 -- Some subgroups of patients with psoriasis are at greater risk for atherosclerotic cardiovascular disease (ASCVD), according to a research letter published online Feb. 20 in JAMA Dermatology. Kathryn A. Arnold, from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 1, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis
CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3) In Phase 3 trials, risankizumab achieved signifi... Biopharmaceuticals, Dermatology, Regulatory AbbVie, SKYRIZI, risankizumab, plaque psoriasis, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis
CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3) In Phase 3 trials, risankizumab achieved signifi... Biopharmaceuticals, Dermatology, Regulatory AbbVie, SKYRIZI, risankizumab, plaque psoriasis, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2019 Category: Pharmaceuticals Source Type: news

New Guidelines Address Management and Treatment of Psoriasis New Guidelines Address Management and Treatment of Psoriasis
Two new joint American Academy of Dermatology-National Psoriasis Foundation guidelines address the management and treatment of psoriasis in adults, focusing on biologics and on comorbidities.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Nervous about needles? FDA OKs Janssen injection device for the squeamish
The Food and Drug Administration on Wednesday granted marketing approval to Janssen Pharmaceutical Co.'s Tremfya One-Press, a patient-controlled injector designed for people with moderate-to-severe psoriasis. Tremfya is Horsham-based Janssen Biotech's biologic treatment approved by the FDA in 2017 for psoriasis, a chronic inflammatory disorder that results in the overproduction of skin cells. The condition causes raised, inflamed, red lesions or plaques — which can result in physical pain and… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 27, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

Janssen Announces U.S. FDA Approval of Novel TREMFYA ® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 27, 2019 Category: Pharmaceuticals Source Type: news

Persistence of Treatment With Biologics in Psoriasis Persistence of Treatment With Biologics in Psoriasis
Do biologics used in the treatment of psoriasis retain their effectiveness over the long-term?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

FDA Approves Tremfya (guselkumab) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
HORSHAM, PENNSYLVANIA, February 27, 2019 - The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya One-Press, a single-dose, patient-controlled injector for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 27, 2019 Category: Drugs & Pharmacology Source Type: news

Psoriasis Effects on CV Risk May be Direct and Vary by Race Psoriasis Effects on CV Risk May be Direct and Vary by Race
' It may still be an independent effect of the psoriasis, but acting through these other traditional risk factors,'said a researcher. Younger African-American adults seemed to be at special risk.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 25, 2019 Category: Dermatology Tags: Cardiology News Source Type: news

Guideline Covers Extracutaneous Manifestations of Psoriasis
FRIDAY, Feb. 22, 2019 -- The extracutaneous manifestations of psoriasis and guidance on use of biologic treatment for management of psoriasis are discussed in two new guidelines published online Feb. 13 in the Journal of the American Academy of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2019 Category: Pharmaceuticals Source Type: news

What Is the Best Treatment for Psoriasis?
Title: What Is the Best Treatment for Psoriasis?Category: Diseases and ConditionsCreated: 2/20/2019 12:00:00 AMLast Editorial Review: 2/22/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - February 22, 2019 Category: Dermatology Source Type: news

5 Noteworthy Cardiovascular Studies from American Heart Month
Psoriasis medication for heart disease prevention, the role of artificial sweeteners in different types of stroke, and 3 other noteworthy findings from American Heart Month.   (Source: ConsultantLive)
Source: ConsultantLive - February 20, 2019 Category: Internal Medicine Authors: Sydney Jennings Tags: Cardiovascular Source Type: news

Clarify Medical wins CMS reimbursement for phototherapy psoriasis treatment
Clarify Medical said today that it won reimbursement coverage through the U.S. Centers for Medicare & Medicaid Services for treatments with its Clarify Home light therapy system for treating psoriasis, effective immediately. The new decision from CMS falls under its National Coverage Determination for the treatment of psoriasis, which includes narrowband ultraviolet B phototherapy, San Diego-based Clarify Medical said. The company’s Clarify system uses narrowband ultraviolet B rays to penetrate the skin and slow the growth of affected skin cells. Studies have found that narrowband UVB rays help to clear psoriasis...
Source: Mass Device - February 12, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cosmetic/Aesthetic Clarify Medical Source Type: news

Psoriasis Tx Linked to Drop in Noncalcified Coronary Plaque
WEDNESDAY, Feb. 6, 2019 -- Treatment of psoriasis with biologic therapy is associated with a reduction in noncalcified coronary plaque and improved plaque morphology, according to a study published online Feb. 5 in Cardiovascular Research. Youssef... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2019 Category: Pharmaceuticals Source Type: news

Medical News Today: Immunosuppressants reduce artery plaque in people with psoriasis
New research finds that a psoriasis treatment that suppresses the immune system can improve the cardiovascular health of those living with psoriasis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 6, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news

Biologic Tx for Psoriasis Tied to Better Heart Health
(MedPage Today) -- Treatment linked with non-calcified coronary plaque reduction, plaque morphology improvement (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 6, 2019 Category: Cardiology Source Type: news

Psoriasis Meds Might Help Fight Heart Trouble, Too
The use of inflammation-suppressing drugs known as biologics appeared to be linked with a slowed buildup of fatty plaques in arteries in a recent study. (Source: WebMD Health)
Source: WebMD Health - February 5, 2019 Category: Consumer Health News Source Type: news

Study links psoriasis treatment and improvement in heart artery disease
Biologic drugs that target immune system activity can reduce the early plaque buildup that clogs arteries. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 5, 2019 Category: American Health Source Type: news

Psoriasis Meds Might Help Fight Heart Trouble, Too
TUESDAY, Feb. 5, 2019 -- Could the inflammation that drives psoriasis and other immune-linked illnesses be a major player in heart disease? In a new study, certain psoriasis drugs appeared to help to keep arteries clear, suggesting such a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 5, 2019 Category: General Medicine Source Type: news

Psoriasis Meds Might Help Fight Heart Trouble, Too
Title: Psoriasis Meds Might Help Fight Heart Trouble, TooCategory: Health NewsCreated: 2/5/2019 12:00:00 AMLast Editorial Review: 2/5/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - February 5, 2019 Category: Cardiology Source Type: news

Psoriasis medication may improve heart disease in patients with the skin condition
(European Society of Cardiology) Anti-inflammatory biologic drugs used to treat severe psoriasis have the potential to prevent heart disease in patients with the skin condition, according to research published today in Cardiovascular Research, a journal of the European Society of Cardiology (ESC). During one year of treatment, biologic therapy improved coronary artery plaque similar to the effect of a low-dose statin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 5, 2019 Category: International Medicine & Public Health Source Type: news

Study links psoriasis treatment and improvement in heart artery disease
(NIH/National Heart, Lung and Blood Institute) Researchers have found that treating psoriasis, a chronic inflammatory skin disease, with biologic drugs that target immune system activity can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke. The findings highlight how immunotherapies that treat inflammatory conditions might play a role in the reduction of cardiovascular disease risks. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 5, 2019 Category: International Medicine & Public Health Source Type: news

Tremfya and Ilymya listed for plaque psoriasis in Australia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news